Table 1.

Workshop key terms

E-cigarette: Electronically powered product delivering an inhalable liquid-based aerosol. This is an umbrella term for all devices that fit this definition (e.g., vaping product, ENDS, e‐hookahs, e‐pipes, vape pens, dab pens, personal vaporizers, etc.). E-cigarettes will be further subdivided by the primary active ingredients as below: •Nicotine e-cigarettes—contain tobacco-derived or synthetic nicotine, currently under FDA purview for regulation. •Cannabinoid e-cigarettes—contain cannabinoids, not currently under FDA regulatory authority. •Other e-cigarettes—contain other active ingredients (e.g., melatonin, vitamins, caffeine, essential oils, etc.), not currently under FDA regulatory authority.

EVALI: This term will be used to refer to all e-cigarette–related lung injury. This term will be used as an umbrella, as the EVALI epidemic has brought attention to e-cigarette–related health effects and is used broadly to document lung injury/disease attributable to e-cigarettes. It should be noted that the CDC does not limit EVALI diagnosis to those exposed to particular active ingredients, and use of all e-cigarettes were considered under the diagnostic criteria.

Definition of abbreviations: CDC = U.S. Centers for Disease Control and Prevention; ENDS = electronic nicotine delivery systems; EVALI = e-cigarette or vaping product use–associated lung injury; FDA = U.S. Food and Drug Administration.